Love Everyone?
Why Vitamin D Could Prevent Autism

Chile and Argentina Test Oxytocin for Chronic Migraine

Trigemina, a company focused on creating non-narcotic pain relief drugs, is enrolling patients in a Phase II clinical trial of inhaled oxytocin to treat chronic migraine. Trigemina's oxytocin product, known as T1-001 (no doubt to be renamed to something lyrical if it comes to market), has already shown promising results in preliminary studies, the company says.

This use makes perfect sense: Oxytocin is a general analgesic (pain reducer), and it also contributes to relaxation and healing.

It's notable that Trigemina specializes in inhalant drugs, and it has a proprietary formulation of oxytocin. Without some market angle, there's little incentive for companies to develop oxytocin-based drugs.

If and when this comes to market, I can see it being prescribed off-label for all kinds of things, including   persistent genital arousal disorder (PGAD) and fibromyalgia.

 

Comments